Digital illustration showing breast cancer cell division into different molecular subtypes, against a radiotherapy background, representing personalized treatment decisions.

Decoding Breast Cancer: Can Molecular Subtypes Predict Recurrence?

Samir D’Costa in Health & Wellness December 2025 • 4 min read.

"New research sheds light on how molecular subtyping can refine post-mastectomy radiotherapy decisions for early-stage breast cancer patients, potentially minimizing unnecessary treatments."

Radiotherapy is a crucial tool in the fight against breast cancer, typically recommended after mastectomy for patients at high risk of recurrence. This includes those with T3 tumors (larger tumors) and those with four or more positive axillary lymph nodes (ALNs). However, the role of post-mastectomy radiotherapy (PMRT) in early-stage breast cancer with 1-3 positive ALNs (pT1-2N1M0) remains a topic of debate.

While some studies suggest no clear survival benefit from regional nodal irradiation in this specific group, others, including meta-analyses, indicate a positive impact. Clinical practice guidelines reflect this uncertainty, recommending PMRT consideration, but highlighting the need for individualized approaches. This underscores the importance of identifying subgroups within this patient population who might genuinely benefit from PMRT.

Recognizing that breast cancer is a heterogeneous disease with varying biological behaviors, researchers have begun exploring the role of molecular subtypes in predicting recurrence. By integrating molecular subtyping with traditional clinicopathologic factors, clinicians may be able to refine treatment strategies and personalize PMRT recommendations, ultimately improving outcomes while minimizing unnecessary radiation exposure. This approach leverages the intrinsic biological features of tumors to make more informed treatment decisions.

Molecular Subtyping: A Key to Personalized Treatment

Digital illustration showing breast cancer cell division into different molecular subtypes, against a radiotherapy background, representing personalized treatment decisions.

A retrospective study investigated the link between molecular subtypes and locoregional recurrence (LRR) in 701 patients with early-stage breast cancer (pT1-2N1M0) who did not undergo PMRT. The research team categorized tumors into four subtypes: luminal A, luminal B, HER2-enriched, and basal-like.

The study revealed significant differences in LRR rates based on molecular subtype. Compared to the luminal A subtype, the HER2-enriched and basal-like subtypes were associated with significantly higher 5-year LRR rates (21.6% and 15.7% respectively, compared to 5.6% for luminal A). This indicates that these subtypes may represent higher-risk groups that could potentially benefit from PMRT.

Luminal A: Generally hormone receptor-positive, HER2-negative, and with low proliferation rates.
Luminal B: Hormone receptor-positive, and either HER2-positive or with high proliferation rates.
HER2-enriched: HER2-positive and typically hormone receptor-negative.
Basal-like: Typically triple-negative (ER-, PR-, HER2-) and often associated with aggressive tumor behavior.

Multivariate analysis identified several independent prognostic factors for LRR and LRR-free survival (LRFS), including HER2-enriched and basal-like subtypes, age ≤35 years, medial tumor location, and pT2 stage. The presence of 2-3 positive ALNs was also an independent prognostic factor affecting LRR. Integrating these factors allowed the researchers to stratify patients into risk groups, demonstrating a clear correlation between the number of risk factors and the likelihood of recurrence.

Refining Treatment Strategies: A Path Towards Personalized Care

The study's findings suggest that molecular subtyping can help individualize LRR risk assessment in patients with pT1-2N1M0 breast cancer. Patients with ≥3 LRR risk factors, particularly those with HER2-enriched or basal-like subtypes, may warrant consideration for PMRT.

Conversely, patients with fewer risk factors might safely avoid PMRT, reducing their exposure to potential side effects without compromising local control. This approach aligns with the broader movement towards personalized medicine, where treatment decisions are tailored to the individual patient's tumor biology and risk profile.

While the study provides valuable insights, it's important to acknowledge its limitations, including its retrospective nature and relatively small sample size. Future research should focus on validating these findings in larger, prospective trials and exploring the potential of incorporating other biomarkers to further refine risk stratification and treatment planning. Ultimately, the goal is to optimize breast cancer treatment, maximizing efficacy while minimizing unnecessary interventions.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.4048/jbc.2016.19.2.176, Alternate LINK

Title: Predictive Value Of Molecular Subtyping For Locoregional Recurrence In Early-Stage Breast Cancer With N1 Without Postmastectomy Radiotherapy

Subject: Cancer Research

Journal: Journal of Breast Cancer

Publisher: Korean Breast Cancer Society

Authors: Ge Wen, Jin-Shan Zhang, Yu-Jing Zhang, Yu-Jia Zhu, Xiao-Bo Huang, Xun-Xing Guan

Published: 2016-01-01

Everything You Need To Know

What is molecular subtyping in breast cancer, and what are the main subtypes?

Molecular subtyping categorizes breast cancer into distinct groups based on the tumor's genetic and protein characteristics. The four primary subtypes are Luminal A, Luminal B, HER2-enriched, and Basal-like. Luminal A tumors are typically hormone receptor-positive and HER2-negative with low proliferation. Luminal B tumors are hormone receptor-positive but may be HER2-positive or have high proliferation rates. HER2-enriched tumors are HER2-positive and usually hormone receptor-negative, while Basal-like tumors are often triple-negative (ER-, PR-, HER2-) and more aggressive.

When is post-mastectomy radiotherapy (PMRT) typically recommended, and what is the debate surrounding its use in early-stage breast cancer?

Post-mastectomy radiotherapy (PMRT) is typically recommended for breast cancer patients at high risk of recurrence, such as those with T3 tumors or four or more positive axillary lymph nodes (ALNs). However, its role in early-stage breast cancer with 1-3 positive ALNs (pT1-2N1M0) is debated. Some studies suggest no clear survival benefit from regional nodal irradiation in this specific group, while others indicate a positive impact, leading to varying clinical practice guidelines.

How do different molecular subtypes affect the risk of locoregional recurrence (LRR) in early-stage breast cancer?

The HER2-enriched and basal-like subtypes were associated with significantly higher 5-year locoregional recurrence (LRR) rates compared to the luminal A subtype. Specifically, the HER2-enriched subtype had a 21.6% LRR rate, and the basal-like subtype had a 15.7% LRR rate, compared to 5.6% for luminal A. These findings suggest that patients with HER2-enriched or basal-like tumors may be at higher risk and could potentially benefit from post-mastectomy radiotherapy (PMRT).

Besides molecular subtypes, what other factors influence locoregional recurrence (LRR) in early-stage breast cancer?

Several independent prognostic factors for locoregional recurrence (LRR) and LRR-free survival (LRFS) have been identified. These include HER2-enriched and basal-like subtypes, age ≤35 years, medial tumor location, pT2 stage, and the presence of 2-3 positive axillary lymph nodes (ALNs). Integrating these factors helps to stratify patients into risk groups, demonstrating a clear correlation between the number of risk factors and the likelihood of recurrence.

How can molecular subtyping be used to personalize treatment decisions and improve outcomes for early-stage breast cancer patients?

The integration of molecular subtyping with traditional clinicopathologic factors allows for personalized locoregional recurrence (LRR) risk assessment in patients with pT1-2N1M0 breast cancer. Patients with ≥3 LRR risk factors, especially those with HER2-enriched or basal-like subtypes, may warrant consideration for post-mastectomy radiotherapy (PMRT). This approach aims to refine treatment strategies, optimize therapy, and minimize unnecessary radiation exposure by leveraging the intrinsic biological features of tumors to make more informed treatment decisions. Further research is needed to explore the optimal treatment strategies for each molecular subtype and risk group.